Fact-checked by Grok 2 weeks ago

Set and setting

Set and setting refers to the psychological predisposition—or "set," encompassing mindset, expectations, and personality—and the physical, social, and cultural environment—or "setting"—that interact with psychoactive substances to shape their subjective effects, particularly in the case of psychedelics like LSD and psilocybin.^[1] This framework underscores that drug-induced alterations are not solely pharmacological but emerge from causal interplay between brain chemistry and contextual variables, as evidenced by consistent reports of divergent outcomes under similar doses but varying preparatory states or surroundings.^[2] Popularized by Harvard psychologist Timothy Leary during his early 1960s research on LSD, the concept formalized observations from clinical trials and indigenous practices, positing that set and setting explain up to 99% of response variability, far outweighing dose alone in uncontrolled scenarios.^[3] Leary's emphasis stemmed from empirical patterns in therapeutic sessions, where supportive environments yielded insights and behavioral changes, while adverse ones precipitated distress.^[4] Contemporary randomized studies confirm this causal role; for instance, varying musical genres within therapeutic settings—classical versus overtone-based—produced higher mystical experience scores and improved abstinence rates in psilocybin treatment for smoking cessation, highlighting setting's modulatory impact on neuroplasticity and subjective intensity.^[5] Expert consensus further prioritizes standardized reporting of set and setting in trials to isolate pharmacological effects from extrapharmacological confounds, enabling replicable benefits in treating depression and addiction.^[6] While unregulated recreational use often ignores these factors, leading to unpredictable risks, controlled optimization in clinical protocols has revived interest, though debates persist over quantification challenges and potential overreliance on subjective preparation amid institutional pushes for psychedelic mainstreaming.^[7]

Conceptual Foundations

Definition and Core Elements

Set refers to the internal psychological and physiological state of the individual at the time of psychoactive substance administration, encompassing mindset, expectations, personality traits, prior experiences with similar substances or states, emotional condition, and bodily preparation such as fatigue or health status.^[8]^[9] This internal configuration shapes how the substance's neurochemical actions are perceived and integrated into subjective experience, with empirical observations indicating that negative expectations or unresolved anxiety can amplify dysphoric responses, while positive preparation correlates with enhanced perceptual clarity.^[10] Setting denotes the external contextual elements surrounding the experience, including the physical environment (e.g., lighting, noise levels, and spatial comfort), social companions (their attitudes and interactions), procedural elements like dosage timing or guidance rituals, and broader cultural norms influencing interpretation.^[11]^[12] These factors provide a scaffold for the unfolding effects, where supportive settings—such as controlled, familiar spaces—facilitate adaptive processing of altered states, whereas chaotic or unsupportive ones may precipitate disorientation or distress, as documented in controlled administrations.^[13] From a causal perspective grounded in pharmacology, set and setting function as modulators that interact with the substance's primary receptor-level actions—such as serotonin 5-HT2A agonism in psychedelics—altering experiential valence and intensity without supplanting the drug's foundational neurobiological drivers.^[10]^[14] Empirical distinctions arise from dose-response relationships, where pharmacological potency sets experiential thresholds that contextual variables refine but cannot fabricate absent the compound's intrinsic activity, underscoring that variability in outcomes reflects combinatorial causality rather than environmental determinism.^[8]

Distinction Between Set and Setting

Set refers to the intrapersonal psychological state of the individual, encompassing mindset, expectations, emotional disposition, personality traits, and beliefs regarding the substance or experience.^[7] This includes factors such as pre-existing anxiety levels or convictions about the drug's effects, which filter perceptions through internal cognitive and affective lenses.^[8] In contrast, setting denotes the extrapersonal context, including the physical environment (e.g., lighting, temperature, architecture), social elements (e.g., presence of guides or companions), and sensory inputs (e.g., music or odors), which provide external stimuli that interact with the drug's neurochemical actions.^[12] This delineation avoids conflation by recognizing set as an endogenous modulator rooted in the user's stable or preparatory psychology, while setting functions as an exogenous scaffold amenable to deliberate design. Temporally, set extends from pre-administration preparation—such as intention-setting or meditation—to the ongoing subjective interpretation during the experience, reflecting dynamic internal processes that evolve with the altered state.^[15] Setting, however, pertains to the immediate and ambient conditions established prior to ingestion, including the session's spatial layout and interpersonal dynamics, which persist as relatively static backdrops unless actively altered.^[7] This temporal distinction underscores set's role in shaping interpretive frameworks over time, whereas setting influences acute sensory and relational inputs that can amplify or attenuate baseline physiological responses. Empirical evidence highlights their differential impacts: personality traits associated with set, such as high openness to experience, robustly predict the intensity of mystical-type experiences and subsequent trait changes in psilocybin administration, independent of environmental variables.^[16]^[17] Conversely, controlled manipulations of setting elements, like varying musical genres during ayahuasca sessions, demonstrably shift emotional content and subjective valence without altering core personality-driven outcomes.^[12] These findings, drawn from randomized designs, affirm set's primacy in modulating depth of insight via intrinsic predispositions, while setting exerts influence through contextual cues, enabling targeted optimization in research protocols.^[10]

Interaction with Pharmacological Effects

Classic psychedelics, including lysergic acid diethylamide (LSD) and psilocybin, primarily induce their effects through agonism at serotonin 5-HT2A receptors, disrupting default mode network activity and enhancing neural plasticity via downstream signaling pathways such as β-arrestin2 and Gq/11 transducers.^[18]^[19] This receptor-level interaction constitutes the causal foundation for perceptual alterations, emotional amplification, and cognitive shifts, independent of external variables.^[20] Set and setting modulate these pharmacological actions secondarily, functioning as top-down cognitive and contextual overlays that amplify or attenuate experiential intensity without altering the drug's molecular binding or primary neurochemical cascade.^[10] Expectancy effects inherent to mindset (set) influence perceptual distortions by priming attentional biases and interpretive frameworks, thereby enhancing the salience of drug-induced sensory anomalies through predictive coding mechanisms in cortical hierarchies.^[21] For instance, pre-existing beliefs about psychedelic outcomes can intensify visual hallucinations or synesthesia via heightened top-down modulation of sensory processing, as evidenced in neuroimaging studies showing amplified prefrontal-limbic interactions under expectation.^[22] Similarly, environmental cues within the setting trigger conditioned associative responses, where familiar or salient stimuli evoke Pavlovian-like reinforcements that either facilitate immersion in altered states or provoke anxiety-driven attenuation of the drug's effects.^[23] This modulation aligns with causal realism, wherein the drug's inherent pharmacodynamics drive core outcomes—such as 5-HT2A-mediated cortical excitation—while set and setting exert influence through bidirectional feedback loops, not as deterministic overrides.^[8] Empirical data underscore that variability in experiences arises from interactions between fixed pharmacological potency and malleable psychological factors, countering narratives that attribute adverse reactions predominantly to suboptimal contexts, which risks understating baseline neurotoxic or psychotomimetic potentials observable even in controlled settings.^[7] Such overemphasis on context, often prominent in advocacy-driven literature, overlooks dose-response consistencies in receptor occupancy and therapeutic windows documented across species.^[24]

Historical Origins

Early Conceptualization in Psychedelic Discovery

The discovery of LSD's profound psychological effects by Albert Hofmann in 1943 prompted early recognition of non-pharmacological influences on experiential outcomes. During his intentional self-administration of 250 micrograms on April 19, 1943—the event later termed "Bicycle Day"—Hofmann experienced intense perceptual alterations exacerbated by his anxious mindset and the unstructured outdoor environment of cycling home from the Sandoz laboratory in Basel, Switzerland, underscoring how internal expectations and external surroundings could amplify or modulate drug-induced states.^[25] In the early 1950s, psychiatrist Humphry Osmond extended these insights through clinical investigations of mescaline and LSD, observing stark variability in subject responses that could not be explained by dosage alone. Osmond noted that identical doses produced divergent reactions ranging from insightful revelations to distressing psychotomimesis, attributing such differences to patients' pre-existing psychological attitudes and the clinical setting's sterility or lack of supportive elements, which often hindered therapeutic potential.^[1] These observations arose amid efforts to model schizophrenia and psychosis, where hospital environments frequently elicited negative outcomes compared to more controlled, preparatory contexts.^[26] Osmond's conceptualization gained empirical grounding in alcoholism treatment trials conducted with Abram Hoffer from 1954 to 1960 at Weyburn Mental Hospital in Saskatchewan, Canada, involving approximately 2,000 patients administered LSD in sessions designed to induce revelatory "delirium" akin to withdrawal states. Outcomes varied significantly, with 40% to 45% of participants abstaining from alcohol for at least one year post-treatment, a success rate Osmond linked to patients' motivational readiness and the intentional framing of sessions to foster self-reflection rather than mere intoxication.^[27] In a 1959 publication, Osmond and collaborators emphasized "extra-drug parameters"—precursors to formalized set and setting—as critical for enhancing LSD's efficacy, prioritizing preparatory mindset alignment and environmental optimization over pharmacological factors alone.^[1] This pre-Leary framework positioned variable psychological and contextual elements as causal determinants of psychedelic reactions, rooted in clinical data rather than theoretical abstraction.

Formulation by Timothy Leary

Timothy Leary first emphasized the importance of psychological preparation and environmental factors in modulating psychedelic effects during the Harvard Psilocybin Project, which he directed from 1960 to 1963 alongside Richard Alpert (later Ram Dass). In this research program, Leary conducted sessions with psilocybin on students, prisoners, and others, observing that outcomes varied markedly based on participants' preconceptions and session contexts rather than solely the substance's pharmacology.^[28] These insights laid the groundwork for distinguishing "set"—the subject's mindset, expectations, and emotional state—from "setting," the physical, social, and procedural environment of the experience.^[29] Leary's formulation gained its most detailed expression in the 1964 book The Psychedelic Experience: A Manual Based on the Tibetan Book of the Dead, co-authored with Alpert and Ralph Metzner.^[30] The manual reinterprets the Tibetan Bardo Thodol as a framework for LSD or psilocybin sessions, dividing the trip into three phases (Chikhai, Chönyid, and Sidpa Bardos) analogous to ego death, visionary encounters, and rebirth. It prescribes preparatory rituals including participant screening for psychological stability, intentional mindset cultivation through meditation or discussion, a calm and aesthetically supportive physical space, fasting beforehand, and the oversight of a sober guide who reads scripted passages to navigate potential distress.^[31] These protocols aimed to maximize therapeutic or mystical outcomes by aligning the experience with Eastern spiritual traditions, marking an innovative shift toward structured, non-medical facilitation.^[29] This approach formalized psychedelic preparation in ways that permeated the 1960s counterculture, where Leary's advocacy—epitomized in slogans like "turn on, tune in, drop out"—encouraged widespread adoption of ritualistic elements such as group sessions in natural settings and emphasis on positive expectancy to foster personal transformation.^[32] Yet, Leary's claims, including that set and setting accounted for 99 percent of psychedelic responses, drew criticism for deriving from anecdotal, unblinded observations in Harvard's loosely controlled experiments, which prioritized subjective reports over rigorous controls and minimized inherent pharmacological potency.^[33] Such promotional overreach arguably sidelined evidence of substance-driven determinism, where molecular interactions at serotonin receptors dictate core perceptual alterations irrespective of context, while underplaying documented risks like hallucinogen persisting perception disorder or induced psychotic breaks in vulnerable individuals.^[34]^[35]

Expansion in Sociological Frameworks

In 1984, psychiatrist Norman E. Zinberg published Drug, Set, and Setting: The Basis for Controlled Intoxicant Use, which formalized a triadic framework incorporating the pharmacological properties of the drug alongside the user's mindset (set) and environmental context (setting), thereby expanding Leary's original formulation beyond psychedelics to encompass a broader range of psychoactive substances including opioids, cocaine, and alcohol.^[36] Drawing from over two decades of clinical observations and field studies of "natural" users—individuals who maintained non-problematic consumption patterns—Zinberg emphasized that controlled use often emerges through iterative social learning rather than inherent pharmacological determinism.^[37] Zinberg's analysis shifted the discourse toward the sociology of drug effects by integrating social norms, rituals, and sanctions as integral components of setting, arguing that these elements modulate outcomes across diverse substances; for instance, his examinations of opioid users in community settings revealed that established group rituals and mutual accountability fostered moderation, contrasting with isolated or chaotic consumption leading to escalation.^[36] Empirical data from his qualitative interviews and case histories indicated that such structured social contexts correlated with lower rates of dependency and overdose among otherwise comparable users, attributing this to learned self-regulation rather than drug type alone.^[38] This generalization highlighted how societal expectations and peer-enforced boundaries could mitigate harms, as evidenced in patterns of controlled intoxication observed in urban cohorts during the 1970s and early 1980s. However, Zinberg's framework, while grounded in observational evidence of harm reduction in controlled scenarios, has been critiqued for potential overemphasis on modifiability, as pharmacological variables like potency and tolerance thresholds impose causal limits not fully overridden by social factors; longitudinal patterns in opioid cohorts, for example, show that even socially embedded users face elevated risks of progression under stress or supply changes, underscoring that empirical associations with positive outcomes do not equate to universal safety or endorsement of use.^[36]^[38] This sociological expansion influenced subsequent policy discussions on decriminalization and harm reduction, prioritizing contextual interventions over blanket prohibition, though subsequent research has refined it to account for individual variability in adherence to norms.^[39]

Theoretical Underpinnings

Psychological and Expectation-Based Mechanisms

Expectancy effects represent a core psychological mechanism through which set modulates psychedelic experiences, as prior beliefs about the substance's effects influence the cognitive appraisal of altered states. In this process, individuals with positive expectations—shaped by cultural narratives, personal history, or preparatory instructions—tend to interpret sensory distortions as meaningful or therapeutic, whereas negative anticipations can exacerbate anxiety and lead to dysphoric outcomes.^[40] This aligns with broader expectancy theory in psychopharmacology, where mindset acts as a lens filtering pharmacological perturbations.^[21] From a predictive processing perspective, the brain's hierarchical inference system generates top-down predictions to anticipate sensory data; psychedelics weaken these priors by enhancing prediction errors, resulting in vivid, unfiltered perceptions that expectations further direct. For instance, optimistic set reduces the weighting of threat-related priors, promoting adaptive reinterpretations of chaos as insight, while anxious set amplifies error signals toward paranoia.^[41] This mechanism underscores how cognitive biases inherent to set causally interact with drug-induced entropy, though without overriding the primary sensory disruptions driven by serotonin receptor agonism.^[42] Stable personality traits, such as openness to experience within the Big Five framework, form enduring elements of set that predict the subjective intensity and valence of psychedelic encounters. Higher openness facilitates engagement with unconventional perceptual shifts, enabling deeper immersion without defensive resistance, as individuals scoring high on this trait exhibit greater baseline tolerance for ambiguity.^[43] Empirical correlations indicate that such traits modulate experience depth independently of dose, reflecting dispositional readiness to integrate novel states rather than transient mood fluctuations.^[44] Neural mechanisms linking set to these outcomes involve amplification of psychedelics' disruption to the default mode network (DMN), a system underpinning self-referential thought whose reduced connectivity under 5-HT2A activation correlates with ego dissolution. A favorable mindset—low in neuroticism and high in positive affect—mitigates countervailing cortical inhibition, allowing fuller expression of DMN desynchronization into phenomenological richness, yet this modulation remains subordinate to dose-dependent receptor occupancy, ensuring pharmacological causality predominates. Thus, while set shapes interpretive layers atop these changes, it cannot engender effects absent sufficient drug loading.^[45] The physical components of the setting, such as lighting, ambient noise, and ergonomic comfort, exert causal influence on psychedelic experiences by altering sensory input during periods of reduced perceptual filtering, a process akin to modulated sensory gating observed in heightened states. Dim, adjustable lighting minimizes visual overstimulation, which can otherwise exacerbate anxiety or perceptual overload, as evidenced in controlled MDMA-assisted therapy protocols where soft illumination correlates with enhanced patient comfort and trauma processing efficacy.^[46] Similarly, low noise environments prevent auditory distractions that disrupt immersive introspection; clinical sessions employing soundproofing or curated music playlists report fewer interruptions to subjective depth compared to uncontrolled naturalistic exposures.^[47] Physical comfort elements, including supportive seating and regulated temperature, further stabilize physiological responses, with trial data indicating that such optimizations reduce somatic distress and support sustained engagement with internal phenomena.^[48] Social dynamics within the setting, particularly the presence of trusted facilitators versus unfamiliar participants, shape perceived safety and emotional trajectories through interpersonal cues that either reinforce or undermine security. In therapeutic contexts, dyadic interactions with trained guides foster rapport, which empirical reviews link to lower rates of acute distress and better post-session integration, as the guide's non-directive support buffers against escalations in vulnerability.^[47] Recreational surveys corroborate this, showing that sober "trip sitters"—experienced, empathetic observers—correlate with diminished challenging experiences, such as paranoia or panic, by providing reassurance without pharmacological interference; one analysis of harm reduction practices found sitters' calming interventions mitigated 70-80% of reported crises in self-reported accounts.^[49] Group settings introduce relational variables like emotional contagion, where synchronized dynamics can amplify positive connectedness but also propagate anxiety if cohesion falters; observational data from ceremonial analogs indicate that heterogeneous groups (e.g., strangers) elevate risk of discordant outcomes compared to pre-vetted pairs, underscoring the need for relational predictability.^[50] Controlled clinical environments, often critiqued for their sterility relative to idealized natural locales, empirically outperform romanticized outdoor settings in facilitating focused introspection and safety, as uncontrolled externalities like variable weather or ambient intrusions introduce noise that dilutes attentional resources. Phase 3 trials of MDMA for PTSD, conducted in standardized rooms with minimalistic aesthetics, achieved serious medical adverse event rates as low as 0.7% (1 episode per 147 participants), attributable to preemptable variables absent in wilderness contexts.^[48] This contrasts with naturalistic reports where environmental unpredictability—e.g., sudden sounds or discomfort—heightens vigilance, diverting cognitive load from therapeutic aims; standardized settings thus enable precise modulation of sensory gating, prioritizing causal efficacy over aesthetic appeal.^[47]

Causal Realism in Effect Modulation

Psychedelic substances exert their effects through direct pharmacological actions, primarily via agonism at serotonin 5-HT2A receptors, which trigger a neurochemical cascade disrupting sensory gating and thalamocortical signaling.^[13] This initiates altered states of consciousness, with set and setting functioning as downstream modulators that influence perceptual salience and emotional valence through top-down attentional processes and learned associations, rather than originating the core perturbations.^[10] Empirical dose-response data reinforce this sequencing, revealing that dosage variations predictably dictate effect intensity across domains like visionary restructuralization and oceanic boundlessness, with sigmoid curves showing pharmacological saturation beyond threshold levels irrespective of contextual interventions.^[51]^[52] In predictive hierarchies derived from controlled administrations, pharmacological specificity and dose rank above set, setting, and genetic factors, as evidenced by consistent scaling of subjective alterations with increasing ligand affinity and quantity, while non-drug variables exhibit weaker, often correlative associations.^[53] This prioritization aligns with causal realism by affirming the drug's agentive role in perturbing neural equilibria, where mindset and environment act as permissive filters rather than deterministic architects. Attributions overelevating set and setting risk understating inherent pharmacological potency, as seen in frameworks that imply experiential outcomes hinge primarily on preparation.^[54] Notions that optimal set and setting render psychedelics reliably benign falter against documented persistent harms, including chronic depersonalization and existential distress following exposures in screened, supportive milieus, where pre-existing vulnerabilities or dosage thresholds precipitate enduring dysregulation beyond contextual safeguards.^[55] Such outcomes highlight the limits of modulation, underscoring that while set and setting can attenuate variance, they cannot nullify the drug's intrinsic liability for adverse neuroplastic shifts in susceptible individuals. This empirical delimitation counters overoptimistic narratives in advocacy circles, which often derive from ideologically inclined interpretations minimizing biochemical primacy.^[56]

Empirical Evidence

Experimental Studies on Set

In the Harvard Psilocybin Project (1960–1962), led by Timothy Leary and Richard Alpert, experimental protocols included preparatory seminars to cultivate a positive mindset among participants before psilocybin administration, with qualitative reports indicating enhanced mystical-type experiences and reduced adverse reactions in prepared cohorts relative to informal or unprepared use.^[13] These sessions involved discussions of expectations, relaxation techniques, and philosophical framing to align mental set with potential perceptual shifts, though the absence of randomized controls limited causal attribution, as environmental factors were not isolated.^[57] Subsequent analyses of early psychedelic trials, including Leary's Concord Prison Experiment (1961–1962), highlighted mindset preparation's role in modulating emotional outcomes, such as lower recidivism claims initially reported (though later contested), underscoring set's influence on interpretive framing rather than pharmacological kinetics.^[58] A 34-year follow-up found sustained behavioral changes in some participants, correlating with pre-experience attitudinal shifts fostered through group therapy, but methodological confounds like selection bias and lack of blinding precluded definitive isolation of set from drug effects.^[59] Modern controlled investigations have employed expectancy manipulations, such as verbal suggestion or pre-dosing narratives, to probe set's impact. In a 2024 analysis of psychedelic trials, expectancy biases via suggestion amplified reported subjective intensity and positive valence (e.g., euphoria ratings increased by 15–20% in high-expectancy groups), yet failed to generate or alter core hallucinatory phenomena like visual distortions, which remained dose-dependent.^[22]^[21] Similarly, a randomized comparison of psilocybin versus escitalopram for depression (2021–2023) measured suggestibility and found mindset priming influenced emotional processing (e.g., higher unity ratings, Cohen's d ≈ 0.4), but not perceptual content, with effects modest relative to pharmacological potency (dose explaining 60–80% of variance in hallucinations).^[60]^[61] Quantitative meta-reviews confirm set's predictive power for affective dimensions—e.g., anxiety reduction or insight generation—over sensory specifics, with regression models showing mindset variables accounting for 10–25% of outcome variance after controlling for dose, though individual differences in trait suggestibility moderate this modestly (r ≈ 0.2–0.3).^[61] These findings derive primarily from blinded suggestion paradigms in LSD and psilocybin studies, revealing set as a secondary modulator rather than a primary driver, consistent with neuroimaging evidence of expectancy enhancing limbic activation without altering serotonergic receptor agonism.^[21] Empirical gaps persist due to ethical constraints on negative set induction and persistent unblinding challenges in high-dose protocols.

Research on Setting Variables

A randomized controlled study published in 2020 examined the impact of musical genres on psilocybin-assisted therapy for tobacco smoking cessation, using a within-subject design where participants received the same dose across sessions paired with either classical music playlists or ambient electronic genres.^[12] Results indicated that playlist type significantly influenced emotional trajectories, with classical music eliciting higher peaks in awe and transcendence ratings on the Mystical Experience Questionnaire, while electronic genres promoted more grounded, introspective states; pharmacokinetic analyses confirmed no alterations in psilocybin metabolism or plasma levels attributable to music.^[12] These findings underscore music as a modifiable setting variable that shapes subjective experience metrics independently of pharmacological effects.^[5] Comparative analyses of clinical versus naturalistic settings reveal that structured therapeutic environments enhance outcome predictability. In MAPS-sponsored phase 3 trials of MDMA-assisted psychotherapy for PTSD, controlled settings with dim lighting, comfortable furnishings, and trained facilitators yielded mean reductions of 24 points on the Clinician-Administered PTSD Scale, alongside lower incidence of acute anxiety spikes compared to self-reported naturalistic MDMA use data from surveys. ^[62] Similarly, a meta-analysis of psychedelic intensity-outcome associations found stronger correlations between experience depth and therapeutic gains in clinical protocols versus uncontrolled settings, attributing this to minimized external distractions and standardized sensory cues.^[63] Such experiments face limitations, including small sample sizes—often n<20 per arm—and confounds from co-varying elements like guide presence, which independently buffers anxiety but is rarely isolated.^[12] Few studies employ double-blind manipulations of non-musical setting factors, such as room aesthetics or noise levels, restricting causal inferences to observational metrics.^[6]

Quantitative Associations with Outcomes

In psilocybin-assisted therapy trials for treatment-resistant depression, higher scores on the Mystical Experience Questionnaire (MEQ), which measures dimensions like unity and transcendence often enhanced by preparatory set optimization, have correlated with sustained symptom remission, with effect sizes indicating r values of 0.18 to 0.33 across aggregated studies.^[64]^[63] A meta-correlation of subjective psychedelic effects, encompassing mystical-type experiences influenced by contextual factors, accounted for 5-10% of variance (R²) in antidepressant outcomes for psilocybin relative to placebo or active controls.^[65] Therapeutic alliance, a set-related variable involving patient-therapist rapport established pre-dosing, has shown positive associations with peak mystical ratings during sessions (r=0.49, p<0.05) in qualitative-quantitative analyses of cancer patients with comorbid depression.^[66] Similarly, setting manipulations like curated music playlists in randomized psilocybin administration yielded differential subjective intensity scores, with classical genres linked to higher emotional breakthrough ratings predictive of mood improvements (p<0.05).^[12] Cross-study syntheses of set variables, such as user motivation and intention-setting, explain portions of variance in post-experience wellbeing and reduced psychopathology, though effect sizes remain modest after adjusting for dose.^[67]^[68] Null associations appear in subsets of data; for example, MEQ scores did not significantly predict anxiety reductions in some psilocybin cohorts despite overall therapeutic gains.^[69] Surveys of non-clinical psychedelic users reveal benefits persisting amid suboptimal set or setting, including positive mood shifts in individuals reporting low baseline wellbeing (odds ratio >1 for lysergics and psilocybin), suggesting dose-related pharmacological effects may predominate over contextual modulation in certain outcomes.^[70]^[7]

Practical Applications

Clinical and Therapeutic Contexts

In clinical protocols for psychedelic-assisted therapy, set preparation involves multiple preparatory psychotherapy sessions to optimize patient mindset, including education on expected effects, psychological screening for contraindications such as cardiovascular risks or history of psychosis, and fostering realistic expectations to mitigate anxiety.^[47] For instance, in MDMA-assisted therapy for post-traumatic stress disorder (PTSD), the Multidisciplinary Association for Psychedelic Studies (MAPS) protocol includes 3-4 non-drug preparatory sessions emphasizing trust-building with therapists and mental rehearsal of the experience, conducted prior to dosing sessions in a controlled clinic environment designed to evoke safety, such as comfortable furnishings and minimal distractions.^[71] Similarly, psilocybin-assisted psychotherapy for major depressive disorder incorporates 6-8 hours of preparatory work to address patient-specific fears and enhance therapeutic alliance, as standardized in phase 2 and 3 trials granted FDA breakthrough therapy designation in 2019 for treatment-resistant depression.^[72] These elements are mandated to standardize outcomes, with therapists trained to monitor and adjust for individual variability in response.^[47] Therapeutic settings are rigorously controlled to minimize external variables, typically involving two co-therapists—one male and one female for balanced dynamics—in a dedicated room free from interruptions, often with eyeshades and music curation to facilitate inward focus during the 6-8 hour dosing period.^[73] Post-dosing integration sessions, numbering 2-3 and lasting 90 minutes each, aid in processing experiences and linking insights to behavioral changes, as seen in protocols for both MDMA and psilocybin where integration correlates with sustained symptom reduction.^[74] FDA-designated breakthrough therapies, such as COMPASS Pathways' COMP360 psilocybin for depression, explicitly require these structured environments to ensure safety and replicability, with trials from 2018 onward demonstrating remission rates of up to 75% at four months in phase 2 studies.^[75] In PTSD applications, MAPS phase 3 trials reported 67% of participants no longer meeting diagnostic criteria after MDMA sessions in optimized settings, attributing partial efficacy to the interplay of pharmacological effects and environmental support.^[76] Despite these achievements, protocols face scrutiny for high implementation costs, estimated at $10,000-15,000 per patient due to extensive therapist time and facility requirements, limiting scalability beyond specialized centers.^[77] Additionally, risk of bias in trials, including therapist expectations influencing patient reports, may overstate set and setting's causal role relative to the drug itself, as evidenced by methodological assessments showing selective outcome reporting and lack of blinding in psychedelic studies.^[78] Empirical gaps persist, with variability in patient responses suggesting that while controlled contexts enhance safety, individual neurobiological factors may dominate efficacy over optimized set alone.^[79]

Recreational and Non-Therapeutic Use

In recreational contexts, users frequently encounter psychedelics such as LSD, psilocybin, or MDMA without structured optimization of set and setting, resulting in unpredictable outcomes ranging from enhanced sociability to acute psychological distress.^[80] Poorly managed mindset—often influenced by pre-existing stress, fatigue, or unresolved emotional issues—combined with uncontrolled environments amplifies the likelihood of challenging experiences, as evidenced by surveys of naturalistic use where inadequate preparation correlates with higher reports of anxiety and confusion.^[49] Party and rave settings exemplify social facilitation through shared euphoria and communal energy, yet they elevate risks of panic and overwhelm due to sensory overload from loud music, dim lighting, overcrowding, and elevated temperatures.^[81] Harm reduction analyses of MDMA and psychedelic use in such venues highlight how these factors, alongside polydrug interactions and lack of sober support, contribute to acute adverse events like paranoia or dissociation, with retrospective accounts indicating that 10-20% of users in festival-like environments report significant distress tied to setting mismatches.^[82] Individual agency in selecting venues and companions becomes paramount, as group dynamics can mask personal vulnerabilities until environmental pressures trigger escalation. Solo recreational use shifts responsibility entirely to self-managed set and setting, yielding variable results where stable personal preparation—such as mental health self-assessment and a secure, familiar space—can foster introspective benefits, but lapses often lead to prolonged isolation-amplified episodes.^[83] Observational data from naturalistic surveys show no overall increase in severe adverse events compared to group use, yet solo contexts demand rigorous personal accountability, with higher variability in outcomes linked to unaddressed predispositions like anxiety disorders.^[84]^[85] This underscores the causal role of individual foresight in averting escalation, contrasting with group normalization that may downplay the need for vulnerability screening among participants.^[55]

Extensions to Non-Psychedelic Interventions

Zinberg's framework of drug, set, and setting has been extended beyond psychedelics to substances like alcohol and tobacco, where social controls function as analogs to setting by moderating consumption patterns and preventing escalation to problematic use. For instance, rituals such as limiting intake to "a drink" during social invitations impose informal boundaries that promote controlled intoxication, as observed in ethnographic studies of habitual users who maintain functionality through learned environmental cues and mindset adjustments.^[86]^[87] In non-drug interventions like cognitive behavioral therapy (CBT) and exposure therapy, analogous principles apply through patient mindset preparation (set) and therapeutic environment (setting), which can enhance efficacy by aligning expectations with procedural demands. Pre-treatment expectation management in exposure therapy, for example, influences task engagement and fear reduction, with studies showing that adjusted threat expectancies correlate with improved outcomes in youth anxiety treatment.^[88] Similarly, the physical and relational ambiance of therapy sessions—such as therapist alliance and room setup—modulates patient responsiveness, akin to setting's role in fostering safety and focus.^[89] Recent proposals advocate importing set-and-setting protocols from psychedelic contexts to general psychiatry to optimize outcomes in routine sessions.^[89] However, empirical support for these extensions remains tentative compared to psychedelic applications, as placebo-controlled studies indicate that mindset and environmental factors exert influence primarily through expectation mechanisms that are less amplified in non-psychedelic contexts lacking profound pharmacological alterations.^[90] General psychotherapy research yields correlational rather than strongly causal data, with variability attributed to individual differences rather than manipulable set-and-setting variables alone.^[91]

Criticisms and Limitations

Empirical Gaps and Methodological Challenges

The vagueness inherent in definitions of set (the user's mindset, expectations, and personality) and setting (the physical and social environment) has significantly impeded replication and empirical validation in psychedelic research. A 2025 review published in PubMed Central argued that such imprecise conceptualizations yield hypotheses resistant to falsification, as they lack operationalized metrics for measurement, thereby undermining the utility of mechanistic models and calling for standardized definitions to facilitate testable predictions.^[7] This definitional ambiguity persists despite decades of invocation since the 1960s, with studies often conflating subjective reports and contextual variables without quantifiable boundaries, resulting in inconsistent findings across trials.^[6] Methodological hurdles further complicate assessment, particularly the infeasibility of double-blinding due to the unmistakable phenomenological effects of psychedelics, which enable participants and investigators to breach blinding integrity. This leads to pronounced expectancy biases, where anticipated outcomes—shaped by cultural narratives or prior knowledge—inflate subjective reports of efficacy independent of drug action.^[92] ^[21] Analyses of trial data have quantified this issue, revealing that unblinded conditions correlate with exaggerated therapeutic attributions, as seen in meta-reviews of psilocybin and LSD studies where placebo responses were amplified by non-specific contextual cues.^[93] ^[94] Empirical gaps are evident in the under-examination of negative set factors, such as unresolved trauma or adverse personality traits, which occur frequently in naturalistic use but receive scant attention relative to optimized preparatory states in clinical protocols. Although real-world surveys indicate that 20-30% of psychedelic users report histories of trauma that may predispose to challenging experiences, controlled studies rarely isolate these variables' causal roles, prioritizing instead positive expectancy manipulations.^[95] ^[56] This selective focus leaves mechanisms of harm—potentially involving heightened emotional volatility or maladaptive coping—largely unquantified, with longitudinal data on adverse trajectories derived mostly from retrospective self-reports rather than prospective designs.^[96]

Overreliance on Anecdotal Reports

Timothy Leary, a key figure in early psychedelic advocacy, posited that set and setting accounted for 99% of the specific response to LSD, drawing from self-reports and observational data across varied experimental conditions in the 1950s and 1960s.^[3] This formulation, while influential, stemmed largely from anecdotal accounts rather than controlled quantification, fostering an overattribution of experiential variance to contextual factors at the expense of drug pharmacology. Such reliance exaggerated set and setting's causal role, as early studies lacked rigorous isolation of variables, permitting subjective narratives to dominate interpretations without empirical falsification.^[7] In modern psychedelic-assisted therapy trials, persistent blinding failures compound this problem, with participants identifying active treatment over 90% of the time due to unmistakable subjective effects, thereby inflating expectancy-driven outcomes misattributed to set or setting adjustments.^[97] Unblinded designs amplify placebo-like responses, where perceived environmental or preparatory influences are credited for therapeutic gains, despite evidence that pharmacological parameters—such as LSD dose and CYP2D6-mediated plasma concentrations—serve as the strongest predictors of effect intensity and type.^[98] Prioritizing pharmacokinetic metrics over testimonial accounts mitigates biases inherent in self-reports, including confirmation tendencies among proponents, enabling causal inference grounded in measurable drug exposure rather than retrospective subjectivity.^[7]^[98]

Individual Variability and Uncontrollable Factors

Individual differences in genetic makeup, particularly polymorphisms in cytochrome P450 enzymes such as CYP2D6, significantly influence the pharmacokinetics and subjective effects of psychedelics, often superseding efforts to optimize set and setting. For instance, CYP2D6 poor metabolizers experience prolonged exposure to active metabolites of LSD due to reduced enzymatic activity, leading to intensified and extended hallucinatory effects that may manifest as anxiety or dissociation regardless of preparatory mindset or environmental controls.^[99] Similarly, ultra-rapid metabolizers exhibit shorter durations but potentially erratic intensity peaks, highlighting how inherited metabolic variability imposes biological constraints on experiential outcomes.^[100] Even in controlled research settings with meticulous attention to set and setting, unpredictable adverse psychological reactions persist, underscoring the limits of contextual optimization. Longitudinal analyses of psychedelic use reveal that challenging or distressing experiences, commonly termed "bad trips," occur in a nontrivial subset of users—estimated at around 10-20% in naturalistic and clinical reports—despite screening for psychological stability and supportive environments.^[101] These episodes, characterized by acute paranoia, panic, or ego dissolution, arise from the inherent stochasticity of psychedelic-induced neural entropy, where heightened brain signal variability defies precise prediction or mitigation through non-pharmacological means.^[55]^[10] This variability emphasizes the causal primacy of the substance's interaction with individual neurobiology over modifiable psychosocial factors, as receptor affinity, endogenous serotonin levels, and latent vulnerabilities can precipitate negative outcomes irrespective of preparation. Overreliance on set and setting risks engendering a false sense of security, as empirical evidence indicates that biological determinism—rooted in genetic and physiological idiosyncrasies—frequently overrides attempts at experiential engineering, with adverse events documented even among prepared participants in therapeutic protocols.^[34] Such findings counsel caution against underestimating the uncontrollable primacy of pharmacological and endogenous drivers in shaping psychedelic responses.

Controversies and Debates

Cultural Bias and Countercultural Origins

The concept of set and setting originated within the 1960s countercultural milieu, where figures like Timothy Leary popularized it as a framework attributing up to 99% of psychedelic response outcomes to psychological preparation (set) and environmental context (setting), rather than pharmacology alone.^[3] This formulation drew from the hippie ethos of spiritual exploration and anti-authoritarian rebellion, embedding a predisposition to interpret drug-induced states as profound, mystical revelations conducive to personal and societal transformation.^[102] Such framing advanced the innovative recognition that non-drug variables profoundly modulate experiences, laying groundwork for contextual interventions in later therapeutic protocols.^[103] However, this countercultural rooting introduced ideological biases favoring permissiveness, as the movement's rejection of conventional norms prioritized unfettered experimentation and equated altered states with inherent wisdom, often sidelining cautions against misuse.^[104] Critics from conservative perspectives have argued that this ethos exemplified moral degeneracy, associating psychedelics with cultural erosion through hedonism and disregard for social order.^[104] In contrast, progressive-leaning narratives in academia and media, which exhibit tendencies toward normalization of countercultural legacies, have amplified positive reinterpretations while critiquing oppositional views as reactionary, potentially underemphasizing hazards of ideologically driven excess.^[105] Despite these biases, the set and setting paradigm achieved partial destigmatization of contextual research by demonstrating how structured environments could mitigate chaotic outcomes, fostering eventual scientific revival beyond recreational contexts.^[104] Yet, detractors contend it inadvertently enabled recreational proliferation by romanticizing uncontrolled settings as pathways to enlightenment, conflating innovation with unchecked libertarian impulses that prioritized individual autonomy over collective safeguards.^[106] This duality underscores the concept's origins as a double-edged contribution: pioneering causal insights into experiential modulation while perpetuating a cultural lens skewed toward affirmative, spiritually inflected valuations.^[103]

Risk Minimization vs. Actual Adverse Events

Proponents of set and setting emphasize that carefully managed psychological preparation (set) and environmental conditions (setting) substantially reduce the incidence of severe adverse outcomes such as hallucinogen persisting perception disorder (HPPD) and drug-induced psychosis during psychedelic use.^[13] In modern clinical trials, where set and setting are rigorously controlled—often involving screened participants, therapeutic support, and supportive environments—serious adverse events (SAEs) like persistent psychosis or requiring medical intervention occur at low rates, typically below 5% across aggregated studies of classic serotonergic psychedelics such as psilocybin and LSD.^[107] For instance, non-serious adverse events (NSAEs) demanding psychiatric attention are reported in fewer than 10% of sessions in controlled protocols, contrasting with recreational contexts lacking such safeguards.^[107] Recreational use, by contrast, shows higher rates of persistent perceptual disturbances, with surveys estimating HPPD prevalence among lifetime psychedelic users ranging from less than 1% to approximately 4.5%, depending on diagnostic criteria and self-report methodologies.^[108] ^[109] These figures suggest that uncontrolled settings may exacerbate risks, as HPPD involves ongoing visual anomalies like trails or geometric patterns persisting months or years post-use, often linked to higher-dose or polydrug recreational patterns.^[110] Proponents attribute the disparity to set and setting's role in modulating expectancy and environmental stressors, which empirical reviews indicate can influence acute experience intensity but lack direct causal proof for preventing long-term harms.^[47] Counterarguments highlight instances of adverse events persisting despite intentional management of set and setting, as in early guided psychedelic sessions from the 1960s onward. Historical case analyses document long-term negative psychological responses, including extended anxiety and perceptual changes, even when users were prepared under frameworks explicitly designed to optimize context, such as those promoted by early researchers.^[55] More recent examples include prolonged psychosis and mood dysregulation following repeated psilocybin administration in structured training environments mimicking therapeutic protocols, underscoring that individual vulnerabilities may override contextual mitigations.^[111] Empirical surveys of broader user populations reveal persistent effects in 1-5% of cases, with symptoms like flashbacks or depersonalization enduring independently of reported setting quality, raising questions about the reliability of set and setting as universal prophylactics against rare but documented casualties.^[112] ^[113] These data, drawn from self-selected cohorts, indicate that while controlled trials minimize acute risks, the preventive efficacy against idiosyncratic long-term sequelae remains empirically uncertain, as no large-scale comparative studies isolate set and setting's causal impact amid confounding factors like dosage and predisposition.^[7]

Political and Legal Ramifications

The enactment of the Controlled Substances Act (CSA) in 1970 classified psychedelics such as LSD and psilocybin as Schedule I substances, denoting high potential for abuse and no accepted medical use, which effectively halted most clinical research in the United States for decades.^[114]^[115] This regulatory framework, part of President Nixon's broader War on Drugs initiated in 1971, imposed stringent requirements on researchers, including DEA oversight and limited funding, prioritizing public safety concerns amid rising recreational misuse and reports of adverse psychological effects in uncontrolled environments.^[116]^[117] Critics attribute the CSA's stringent scheduling to a moral panic driven by anti-countercultural sentiments rather than purely empirical evidence, as Nixon administration officials later acknowledged targeting hippie and anti-war movements through drug policy, despite promising pre-1970 studies on psychedelics for therapeutic applications.^[118] Proponents of the scheduling, however, emphasize evidence-based caution, citing the era's documented risks of unsupervised use—such as "bad trips" exacerbated by poor set (mindset) or setting (environment)—and the absence of standardized safety protocols, which justified restrictions to prevent widespread societal harm. This tension highlights a causal disconnect: while early research suggested benefits under controlled conditions, the policy response conflated therapeutic potential with recreational excesses, stifling empirical validation for years. In recent years, decriminalization efforts have incorporated set and setting principles into policy design to mitigate risks. Oregon's Measure 109, approved by voters in November 2020, established the nation's first regulated psilocybin service program, requiring licensed facilitators to prepare clients psychologically (addressing set) and conduct sessions in controlled centers (optimizing setting), with personal possession outside these frameworks remaining prohibited.^[119]^[120] Similar municipal decriminalizations, such as Denver's Ordinance 301 in 2019 and expansions in cities like Oakland, Berkeley, and Washington state locales by 2025, have deprioritized enforcement of personal psychedelic possession but often stop short of full legalization, leaving federal Schedule I conflicts unresolved and complicating implementation.^[121]^[122] These reforms fuel debates between advocates for expanded therapeutic access—who argue that rigid scheduling ignores set-and-setting-optimized benefits and perpetuates unnecessary criminalization—and skeptics wary of unsupervised use eroding social norms, as naturalistic settings increase risks of acute distress or polysubstance interactions without safeguards.^[123]^[124] Enforcement challenges persist, including federal-state tensions and reports of adverse events in less-regulated contexts, underscoring causal realism: while decriminalization reduces arrests, it demands rigorous guidelines to avert harms from variable individual factors and environments.^[125]

Recent Developments

Standardization in Modern Trials

In response to inconsistencies in prior psychedelic research, an international expert panel conducted a Delphi consensus process in 2025 to establish the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines, published in Nature Medicine on June 3, 2025.^[6] These guidelines specify 22 items for mandatory reporting across categories such as physical environment, dosing room features, therapeutic alliance, and post-session integration support, aiming to enhance trial transparency and replicability by quantifying contextual factors previously described vaguely.^[6] The process involved 43 experts from 12 countries across three iterative rounds, achieving consensus on items that facilitate meta-analyses and regulatory review.^[126] Modern protocols increasingly incorporate standardized elements to isolate set and setting effects, including curated music playlists tailored to psychedelic pharmacokinetics—for instance, instrumental tracks progressing from tension-building to resolution phases during psilocybin sessions to guide emotional arcs without lyrical distraction.^[5] Blindfolding or eye shades are routinely employed to minimize external visual stimuli, directing attention inward and standardizing sensory deprivation across participants, as seen in phase 3 trials for depression and anxiety.^[127] These measures, refined post-2020, address variability in uncontrolled settings by enforcing session uniformity, such as ambient lighting and facilitator training in non-directive support.^[128] A 2025 review emphasized that such standardization reduces descriptive ambiguity in set and setting documentation, enabling better causal attribution of outcomes to pharmacological versus contextual variables and improving reproducibility in multicenter trials.^[7] By mandating detailed logs of environmental acoustics, participant-therapist interactions, and expectancy priming, these advancements mitigate confounds that undermined earlier studies, supporting FDA-aligned evidence generation.^[129] Empirical validation of these protocols continues, with ongoing trials testing their impact on outcome variance.^[130]

Emerging Research on Predictors

A 2021 systematic review of states and traits related to acute psychedelic effects identified personality factors such as trait absorption and openness to experience, alongside baseline mood and expectancy, as robust predictors of positive subjective responses across various psychedelics including psilocybin and LSD.^[131] These traits explained variance in mystical experiences and emotional breakthroughs, with higher absorption correlating to intensified perceptual alterations and reduced anxiety during sessions.^[131] Subsequent prospective studies reinforced that expectancy—shaped by pre-session preparation and therapeutic rapport—moderates outcomes, often amplifying therapeutic insights when aligned with set (mindset) components like motivation for change.^[98] Research from 2024 onward has linked optimized set and setting metrics to enhanced remission rates in mood disorders, particularly treatment-resistant depression. For instance, controlled psilocybin trials optimizing environmental cues (e.g., calming settings with supportive guides) reported sustained symptom reduction in 60-80% of participants at 6-month follow-ups, attributing causality to reduced acute distress via expectancy alignment.^[132] A 2025 analysis of phase 2 trials further demonstrated that higher experiential intensity, forecasted by pre-treatment set assessments (e.g., trait resilience scores), predicted antidepressant efficacy, with optimized settings yielding 2-3 times greater odds of remission compared to suboptimal conditions.^[63] These findings underscore set/setting as modifiable levers for outcome prediction, though causality remains inferred from correlational designs emphasizing psychological preparation over pharmacological dose alone.^[133] Persistent methodological gaps include overreliance on retrospective self-reports for set/setting evaluation, which introduce recall bias and limit predictive precision.^[134] Emerging calls advocate integrating biomarkers—such as EEG-derived neural entropy or cortisol profiles—to objectively forecast responses, potentially surpassing subjective metrics in identifying at-risk individuals for adverse reactions.^[135] While 2025 Delphi consensus guidelines standardize reporting of extra-pharmacological variables, they highlight the absence of validated biomarkers as a barrier to scalable prediction models in clinical settings.^[6]

Forensic and Broader Societal Implications

A 2020 review in the Journal of the American Academy of Psychiatry and the Law analyzed PubMed data linking psychedelics such as LSD and psilocybin to violence, identifying 136 publications on associations with homicide or murder, including case reports of individuals committing fatal acts shortly after use despite purportedly controlled conditions.^[136] These incidents, though infrequent, involved scenarios where psychological preparation and environmental safeguards—core to set-and-setting doctrine—failed to avert acute agitation escalating to lethal outcomes, as in documented homicides attributed to hallucinogen-induced perceptual distortions.^[136] Forensic evaluations in such cases often grapple with distinguishing drug effects from preexisting vulnerabilities, underscoring limitations in relying solely on set and setting for risk mitigation in legal accountability assessments.^[136] Broader societal implications arise from the psychedelic resurgence, where decriminalization efforts in locales like Oregon (Measure 109, effective 2023) and increasing clinical trials may normalize unsupervised use, potentially overlooking baseline risks of addiction reinforcement or psychosis onset in predisposed individuals.^[137] Longitudinal data from naturalistic settings indicate elevated odds of persistent mental health deterioration post-psychedelic exposure among those with latent psychotic traits, with one 2023 analysis reporting heightened incidence of prolonged symptoms akin to schizophrenia in non-clinical users.^[138] This normalization trajectory, amid promotional narratives in media and policy, risks underemphasizing empirical evidence of adverse events, such as cardiovascular strain or hallucinogen persisting perception disorder, which affect 4-10% of users per meta-analyses.^[139] Psychiatric discourse on these risks is complicated by historical patterns of opposition to psychedelic inquiry, as detailed in a 2024 CNS Spectrums perspective, which attributes field-wide credibility erosion to mid-20th-century regulatory suppressions influenced by cultural panics rather than comprehensive data, fostering selective emphasis on benefits over harms in contemporary advocacy.^[35] Such dynamics have led to uneven sourcing in public health guidelines, where proponent-led studies predominate, potentially inflating perceptions of set-and-setting efficacy while marginalizing outlier forensic data on uncontrolled real-world harms.^[35]

References

[1]
Constructing drug effects: A history of set and setting - Sage Journals
Set and setting is a term which refers to the psychological, social, and cultural parameters which shape the response to psychedelic drugs.
[2]
History and Current Status of Psychedelics and Entactogens ... - NCBI
... Humphrey Osmond, who coined the term ... Two extrapharmacological variables—set and setting—greatly influence the outcome of treatment, he said.Missing: origin Humphry
[3]
[PDF] The American Trip: Set, Setting, and Psychedelics in 20th Century ...
Leary went as far as to claim that 99% percent of the specific response to LSD is determined by set-and-setting. Set-and-setting go a long way in explaining the ...Missing: coined | Show results with:coined
[4]
How To Get the Most Out of Your Psychedelic Experience - Numinus
Feb 17, 2023 · The term 'set and setting' formally entered the psychedelic lexicon on September 9th, 1961 when Harvard researcher Timothy Leary presented a ...Missing: definition origin
[5]
Set and Setting: A Randomized Study of Different Musical Genres in ...
... empirically ... This study provides the first contemporary and within-subject experimental manipulation of session set and setting factors in psychedelic research ...
[6]
An international Delphi consensus for reporting of setting in ... - Nature
Jun 3, 2025 · A guiding axiom of the psychedelic paradigm is that psychedelics' pharmacological effects interact with extra-pharmacological variables in ...
[7]
What are set and setting: Reducing vagueness to improve research ...
May 26, 2025 · After decades of regulatory and social barriers, psychedelic research is resurgent on a wide variety of compounds. Classic psychedelics are ...
[8]
The Evolved Psychology of Psychedelic Set and Setting - Frontiers
Phenomenal evidence indicates that the brain's innate intelligences, modular structures and cognitive operators are liberated by psychedelics, with their ...
[9]
https://journals.sagepub.com/doi/10.1177/02698811251338214
[10]
Pharmacological, neural, and psychological mechanisms underlying ...
Systematic research on the role of set and setting on the psychedelic ... These receptor-mechanisms may underlie the therapeutic effects of psychedelics on ...
[11]
Therapeutic setting as an essential component of psychedelic ...
Nov 2, 2022 · The purpose of this paper is to: (1) present what is known of the influence and implications of setting to psychedelic-assisted therapies.
[12]
Set and Setting: A Randomized Study of Different Musical Genres in ...
Dec 29, 2020 · Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but ...
[13]
Psychedelics and Psychedelic-Assisted Psychotherapy
Feb 26, 2020 · It is believed that a therapeutic set and setting make adverse outcomes less likely even when challenging and painful experiences arise.
[14]
Psychedelic therapies reconsidered: compounds, clinical indications ...
Jul 21, 2023 · Set and setting have long been recognized as fundamental elements driving the clinical outcomes of psychedelic administration [104], but more ...
[15]
A rapid narrative review of the clinical evolution of psychedelic ...
Jul 2, 2024 · ... setting in psychedelic clinical trials. Article ... psychedelics, these questions have yet to be the focus of rigorous empirical studies.<|separator|>
[16]
Mystical Experiences Occasioned by the Hallucinogen Psilocybin ...
A large body of evidence, including longitudinal analyses of personality change, suggests that core personality traits are predominantly stable after age 30 ...
[17]
Psychedelic benefits may partially depend on your personality, new ...
Aug 9, 2025 · “The Big Five trait Openness seems to be a very strong predictor for many outcomes before, during, and after a psychedelic experience,” Kajonius ...
[18]
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling ...
Studies indicate that several effects of hallucinogens involve agonist activity at the serotonin 5-HT 2A receptor.
[19]
Identification of 5-HT2A receptor signaling pathways associated with ...
Dec 15, 2023 · Although 5-HT 2A receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT 2A -Gq/11 and β-arrestin2 transducers, making ...
[20]
Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in ...
Nov 8, 2023 · The multiple targets of serotonergic psychedelic drugs. Among the major anatomic targets for serotonergic psychedelics are cortical areas, such ...
[21]
Review Expectancy Effects in Psychedelic Trials - ScienceDirect.com
Clinical trials of psychedelic compounds like psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltrptamine (DMT) have forced a reconsideration of ...
[22]
Expectancy Effects in Psychedelic Trials - Biological Psychiatry
Clinical trials of psychedelic compounds like psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltrptamine (DMT) have forced a reconsideration of ...
[23]
The influence of psilocybin on subconscious and conscious ...
May 18, 2024 · ∙ Preller, K.H.. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat. Rev. Neurosci. 2020; 21:611-624.Results · Psilocybin Led To Higher... · Discussion
[24]
Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the ...
... activation induced by psychedelics must operate to elicit persistent long-term effects. It is known that psychedelic-induced 5HT2AR canonical signalling ...
[25]
High Times | Science History Institute
Feb 2, 2017 · He decided to experiment on himself. Three days later Hofmann ingested 0.25 milligrams of lysergic acid and recorded his reactions in his ...
[26]
Clinical Applications of Hallucinogens: A Review - PMC
... set and setting” on the subjective effects of psilocybin (Leary et al., 1963) ... For our purposes, the atypical hallucinogens are defined as substances capable of ...
[27]
Humphry Osmond - PMC - NIH
Producing a terrifying artificial delirium might frighten an alcoholic into change. Between 1954 and 1960, Osmond and Hoffer treated about 2000 alcoholics under ...Missing: early trials
[28]
The Harvard Psilocybin Project 1960-1963 Introduction
Jan 29, 2025 · Led by Timothy Leary and Richard Alpert (later known as Ram Dass), the Harvard Psilocybin Project dared to explore uncharted territory: the ...
[29]
Constructing drug effects: a history of set and setting
Leary's most comprehensive account of set and setting can be found in The Psychedelic Experience: A Manual Based on the Tibetan Book of the Dead (1964).
[30]
A Manual Based on the Tibetan Book of the Dead (1964)
The Psychedelic Experience: A Manual Based on the Tibetan Book of the Dead ... The book emphasizes the importance of “set and setting” and includes ...
[31]
[PDF] The Psychedelic Experience.Pdf - Leathersmithe
Following the Tibetan model then, we distinguish three phases of the psychedelic experience. The first period. (Chikhai Bardo) is that of complete transcendence ...
[32]
Consciousness Expansion and Counterculture in the 1960s and ...
Apr 2, 2009 · Tim Leary's approach was radically different, though it was not, as some believed, opposed to psychiatric research being done with psychedelics.
[33]
Why the Scientific and Medical Establishments Have Such Biased ...
Jul 17, 2013 · Leary went as far as to claim that 99 percent of the specific response to LSD is determined by set-and-setting.Set-and-setting go a long way in ...Missing: criticisms formulation anecdotal
[34]
Adverse effects of psychedelics: From anecdotes and misinformation ...
This narrative review examines the evidence for potential harms of the classic psychedelics by separating anecdotes and misinformation from systematic research.Missing: criticisms formulation
[35]
The historical opposition to psychedelic research and implications ...
Nov 21, 2024 · Major methodological biases were highlighted, including the lack of standardized measures, randomization procedures, adequate sample ...Missing: formulation | Show results with:formulation
[36]
[PDF] Drug Set and Setting - Zinberg N - Southwest Recovery Alliance
The viewpoint toward the use of illicit drugs expressed in this book has developed gradually during more than twenty years of clinical experience with drug ...<|control11|><|separator|>
[37]
The Basis for Controlled Intoxicant Use: Zinberg, Norman E. (New ...
With the publication of Drug, Set, and Setting,. Norman Zinberg sums up two decades of clinical research on the interactions of people with psychoactive.Missing: summary key
[38]
Circumstances of Overdose Among Street-Involved, Opioid-Injecting ...
Feb 18, 2020 · ” Zinberg's “drug, set, and setting” theoretical framework was applied to identify patterns in circumstances leading up to women's overdose.
[39]
Sage Academic Books - Key Concepts in Drugs and Society
Drug, Set and Setting. The notion of how variable drug effects related to social and psychological contexts was championed by American psychiatrist, Dr Norman ...Missing: findings | Show results with:findings
[40]
The Intricate Interaction Between Expectations and Therapeutic ...
The term set refers to the mindset of the patient, or the mental state a person brings to the experience, including their thoughts, mood, and expectations.
[41]
How Psychedelic-Assisted Treatment Works in the Bayesian Brain
A Pharmacological View on Psychedelic-Assisted Treatment. There are three drugs that are normally clustered as psychedelics: d-lysergic acid diethylamide (LSD), ...
[42]
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain ...
Psychedelic (mind-manifesting) drugs such as d-lysergic acid diethylamide (LSD) and psilocybin are capturing people's imagination and permeating popular culture ...Ii. The Rebus Model · 1. Psychosis · F. Psychedelics And Insight
[43]
Personality traits explain the relationship between psychedelic use ...
May 3, 2024 · These results have implications on how we view psychedelic users and the use of psychedelic drugs. Keywords: Mental health, Psychedelics, Drug ...
[44]
Predicting the Intensity of Psychedelic-Induced Mystical and ... - NIH
Oct 5, 2023 · Potential predictors include personality traits, affect, and dosage; other potential factors include individual factors, such as age, biological ...
[45]
Psilocybin-induced default mode network hypoconnectivity is ...
Dec 14, 2023 · ... DMN-network integrity correlate with the psychedelic ... REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics.Missing: mindset | Show results with:mindset
[46]
https://doi.org/10.1177/0269881118806297
[47]
Therapeutic setting as an essential component of psychedelic ...
Nov 3, 2022 · The purpose of this paper is to: (1) present what is known of the influence and implications of setting to psychedelic-assisted therapies.
[48]
https://doi.org/10.1007/s00213-019-05249-5
[49]
Are you tripping comfortably? Investigating the relationship between ...
Jul 24, 2022 · In this mixed methods online survey study, we aimed to develop an understanding of frequently used psychedelic harm reduction practices in recreational ...Missing: outcomes | Show results with:outcomes
[50]
Psychedelics, Sociality, and Human Evolution - Frontiers
Typical psychedelics such as psilocybin and lysergic acid diethylamide (LSD) modify fundamental brain processes that normally serve to constrain neural systems ...Missing: trusted | Show results with:trusted
[51]
Dose–response relationships of psilocybin-induced subjective ... - NIH
After ingestion, psilocybin is rapidly dephosphorylated to psilocin (4-hydroxy-N,N-dimethyltryptamine), which is mainly responsible for the psychedelic effects ...
[52]
Dose-response relationships of LSD-induced subjective ... - Nature
May 9, 2023 · Here, we will refer to classic serotonergic psychedelics and the effects they induce when using the term 'psychedelics' or 'psychedelic ...
[53]
The Subjective Effects of Psychedelics Are Necessary for Their ...
Dec 10, 2020 · These studies have shown classic psychedelics to fairly reliably occasion mystical experiences. Moreover, classic-psychedelic-occasioned ...<|separator|>
[54]
Unifying Theories of Psychedelic Drug Effects - Frontiers
Furthermore, effects are influenced by non-drug factors traditionally referred to as set and setting, such as personality, pre-dose mood, drug session ...
[55]
Case analysis of long-term negative psychological responses to ...
Sep 25, 2023 · The present study sought to identify and examine long-term negative psychological responses to psychedelic drugs, where 'long-term' was defined ...Results · Phase 2: Interview Phase · Qualitative Analyses
[56]
Extended difficulties following the use of psychedelic drugs
The most common forms of extended difficulty were feelings of anxiety and fear, existential struggle, social disconnection, depersonalization and derealization.Missing: optimal | Show results with:optimal<|separator|>
[57]
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and ...
May 17, 2017 · Catalyzed by early reports on the unique potency and remarkable subjective effects of lysergic acid diethylamide (LSD) in the early 1950s, ...
[58]
Dr. Leary's Concord Prison Experiment: a 34-year follow-up study
The original study involved the administration of psilocybin-assisted group psychotherapy to 32 prisoners in an effort to reduce recidivism rates. This follow- ...Missing: preparation seminars
[59]
Dr. Leary's Concord Prison Experiment: A 34 Year Follow-Up Study
Based upon the preliminary evidence, Leary speculated that psilocybin experiences might be powerful catalysts of behavior change in subjects with criminal ...Missing: seminars | Show results with:seminars
[60]
Assessing expectancy and suggestibility in a trial of escitalopram v ...
Jan 22, 2024 · In this paradigm, psychedelics – such as psilocybin and lysergic acid diethylamide (LSD) – are assumed to interact positively with ...
[61]
Great Expectations: recommendations for improving the ...
Arguably, expectations at baseline may be predictive of subjective effects during the psychedelic session, and expectations at post-session may be ...
[62]
Reduction in social anxiety after MDMA-assisted psychotherapy with ...
Sep 8, 2018 · This pilot trial demonstrated rapid and durable improvement in social anxiety symptoms in autistic adults following MDMA-assisted psychotherapy.
[63]
The intensity of the psychedelic experience is reliably associated ...
In recent years, psychedelic-assisted psychotherapies have shown accumulating empirical evidence ... Set and setting, psychedelics and the placebo response ...
[64]
The Mystical Experience Questionnaire 4-Item and Challenging ...
These correlations were all significant and small-to-medium in effect size (r values = 0.18–0.21, p < 0.001) indicating that greater mystical experience scores ...
[65]
Meta-correlation of the effect of ketamine and psilocybin induced ...
Oct 6, 2024 · Our study demonstrated a modest role for subjective effects mediating therapeutic outcomes, with R2-values ranging from 5–10% for ketamine and ...
[66]
https://www.researchgate.net/publication/396476030_Set_and_setting_in_psilocybin-assisted_therapy_A_qualitative_study_of_patients_with_cancer_and_depression
[67]
Explained variance attributed to the setting and intention cluster...
Taken together, these findings suggest that intention setting may facilitate successful outcomes and minimize negative outcomes of a psychedelic session. ...
[68]
Set and setting predict psychopathology, wellbeing and ... - PubMed
Jan 29, 2024 · The aim of this study is to correlate variables of set (psychedelic use motivation) and setting (psychedelic use location and type of companion) ...
[69]
Psychedelics, Mystical Experience, and Therapeutic Efficacy
Jul 11, 2022 · It includes features such as oceanic boundlessness, ego dissolution, and universal interconnectedness, which have been closely linked to both ...Introduction · Methods · Results · Discussion<|separator|>
[70]
Reported effects of psychedelic use on those with low well-being ...
Jan 30, 2020 · Individuals with low well-being were more likely to experience a positive mood change after use of lysergic acid diethylamide, psilocybin or ...
[71]
[PDF] A Manual for MDMA-Assisted Psychotherapy in the Treatment of ...
The Multidisciplinary Association for Psychedelic Studies (MAPS) is sponsoring clinical trials to explore the potential risks and benefits of 3,4-methylenedioxy ...
[72]
Patient perspectives and experiences with psilocybin treatment for ...
Feb 5, 2024 · Psilocybin treatment for major depressive disorder (MDD) and TRD has recently been awarded 'breakthrough therapy' status by the FDA15.
[73]
Psychedelic-Assisted Therapy for PTSD - National Center for PTSD
Both MDMA-AT and P-AT protocols emphasize "set and setting", or the preparation of the patients for medicine administration as well as the creation of a safe ...
[74]
Study protocol for “MDMA-assisted therapy as a treatment for major ...
A total of nine 90-min non-drug preparatory and integrative psychotherapy sessions will precede and follow the MDMA dosing sessions. Dosing sessions are ...
[75]
FDA Breakthrough Therapy Designation Granted to Novel ...
Mar 14, 2024 · At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.
[76]
Bringing MDMA-assisted therapy for PTSD to traditional healthcare ...
Jan 22, 2025 · In this article, we describe the importance of set and setting in MDMA-AT for PTSD and outline the advantages and challenges of implementing this novel ...Importance of set and setting · MDMA-AT for PTSD · Implementation of MDMA-AT...
[77]
The economics of psychedelic-assisted therapies: A research agenda
Dec 5, 2022 · According to a 2021 survey, 75 percent of therapists reported they would be unlikely to provide psychedelic therapy if it meant a reduction in ...
[78]
Risk of bias in randomized clinical trials on psychedelic medicine - NIH
Jul 4, 2023 · Expectancy is regarded as a key contributing factor to placebo response in RCTs. This has been shown in a meta-analysis to influence the ...
[79]
Protocols and practices in psilocybin assisted psychotherapy for ...
The objective of this review is to summarize and compare current psychotherapy methods of PAP in treating depression and distress in life-threatening illnesses.
[80]
Are you tripping comfortably? Investigating the relationship between ...
In this mixed methods online survey study, we aimed to develop an understanding of frequently used psychedelic harm reduction practices in recreational ...Missing: outcomes | Show results with:outcomes
[81]
A thematic analysis of MDMA-related harm and harm reduction ... - NIH
May 23, 2024 · Wider consideration of set and setting factors such as overcrowding, high temperatures and improper ventilation, and a lack of friends present, ...
[82]
Perceived adverse consequences associated with MDMA/Ecstasy ...
Shewan et al. Perceived risk and risk reduction among ecstasy users: The role of drug, set, and setting ... Patterns and trends of MDMA use and sexual risk ...
[83]
Self-Medicating Alone with Psychedelics: Risks & Harm Reduction
Apr 9, 2024 · Understand the risks of self-medicating alone with psychedelics and learn about harm reduction techniques to ensure safer experiences.
[84]
In naturalistic psychedelic use, group use is common and ...
Jun 19, 2023 · Naturalistic psychedelic users are as likely to report an overall positive outcome and no more likely to report adverse events in group settings than in solo ...
[85]
Harm reduction practises for users of psychedelic drugs - NIH
Oct 3, 2025 · People reported different forms of emotional support ranging from formal guides (most likely in ceremonial settings), trip sitters (either ...
[86]
Drug, Set, and Setting - Yale University Press
Feb 11, 1986 · This discussion by a leading expert on drug use illuminates the factors that permit some people to use such highly addictive and dangerous substances as ...
[87]
Drug, Set, and Setting - Drug Library
Drug, Set, and Setting. The Basis for Controlled Intoxicant Use. Norman E. Zinberg, M.D.. Contents. Preface · 1 Historical Perspectives on Controlled Drug ...
[88]
The Impact of Treatment Expectations on Exposure Process and ...
This study examined the relationship between caregivers' and youths' treatment expectations and characteristics of exposure tasks (quantity, mastery, ...
[89]
https://www.tandfonline.com/doi/full/10.1080/09540261.2024.2419662
[90]
Harnessing placebo: Lessons from psychedelic science - PMC
Finally, in psychedelics research, pre-dosing session therapeutic alliance was found to predict the intensity of the acute psychedelic experience, which in turn ...
[91]
Change of Threat Expectancy as Mechanism of Exposure-Based ...
Oct 4, 2022 · High threat expectancy but low occurrence and adjusted expectancy indicated successful violation and change of threat beliefs by exposure.
[92]
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Sep 5, 2022 · We argue that although psychedelic trials are likely to significantly overestimate treatment effects by design due to unblinding and expectancy effects, this ...
[93]
Expectancy Effects, Failure of Blinding Integrity, and Placebo ...
Mar 12, 2025 · Treatment expectations can lead to unblinding during RCTs, and meta-analytic data from studies in the fields of psychedelics and anxiety ...
[94]
Risk of bias in randomized clinical trials on psychedelic medicine
Jul 4, 2023 · Furthermore, we will review blinding of intervention and to what extent clinical trials reported on expectancy and therapeutic alliance.
[95]
Investigating the associations of acute psychedelic experiences and ...
Evidence suggests that psychedelics may effectively reduce substance use; however, REM people are often underrepresented in psychedelic studies and constructs ...
[96]
Race as a component of set and setting - AKJournals
Mar 1, 2020 · ... set and setting, may affect psychedelic experiences. Race as a ... psychedelics studies. Although this may seem like an act of ...
[97]
Therapeutic potential of psychedelic drugs: navigating high hopes ...
But cloaking such goals in medicalization is bad for public health and for trust in medicine (Shover & Humphreys, 2019). For example, based on weak ecological ...
[98]
Pharmacological and non-pharmacological predictors of the LSD ...
Sep 4, 2024 · The aim of this study was to determine pharmacological and psychological predictors of the LSD effects in healthy human subjects.
[99]
Genetic influence of CYP2D6 on pharmacokinetics and acute ...
May 25, 2021 · These findings indicate that genetic polymorphisms of CYP2D6 significantly influence the pharmacokinetic and subjective effects of LSD.
[100]
Microbiome: The Next Frontier in Psychedelic Renaissance - MDPI
Genetic variations play a critical role in the metabolism and effects of psychedelics. Cytochrome P450 enzymes, primarily CYP2D6, metabolize many psychedelics, ...
[101]
Study explores the enduring positive, negative consequences of ...
Jan 4, 2017 · 10.7% of the respondents said they put themselves or others at risk for physical harm during their bad trip ... Tagged hallucinogens, psychedelics ...Missing: 10-20% | Show results with:10-20%
[102]
How Set and Setting Shape Psychedelic Cultures - Chacruna Institute
Jul 30, 2020 · Cultural values, which inform societies and their perception of reality, determine the collective set and setting conditions, which frame ...
[103]
Constructing drug effects: A history of set and setting
Apr 9, 2024 · Set and setting is a term which refers to the psychological, social, and cultural parameters which shape the response to psychedelic drugs.Missing: definition origin
[104]
Historicizing psychedelics: counterculture, renaissance, and the ...
Sep 21, 2023 · Thus, historicizing psychedelics within the shifts in political economy and culture associated with the “collective set and setting” of ...<|separator|>
[105]
Psychedelics Journalism is Biased - AllSides
Aug 28, 2025 · Pro-psychedelic bias is an example of media bias that falls outside the left-right political spectrum. It's unclear whether the FDA, under ...Missing: wing normalization academia
[106]
The Rise of 1960s Counterculture and Derailment of Psychedelic ...
Aug 9, 2024 · The entanglement of psychedelics with the volatile 1960s counterculture not only led to their ban but also stifled a potentially groundbreaking ...
[107]
Adverse Events in Studies of Classic Psychedelics - JAMA Network
Sep 4, 2024 · ... uses of classic or serotonergic psychedelics ... Rates of SAEs and NSAEs Requiring Medical or Psychiatric Intervention in Psychedelic Studies.
[108]
Prediction of hallucinogen persisting perception disorder and ...
Apr 22, 2025 · While the DSM-V proposes a prevalence of HPPD in 4–4.5% of psychedelic drug users (American Psychiatric Association, 2013), a questionnaire- ...
[109]
One Third Report HPPD After Psychedelics - Conexiant
Apr 28, 2025 · “The frequency of HPPD among psychedelic users overall would thus be estimated at < 1%, which is at least four times lower than the estimate ...<|separator|>
[110]
Hallucinogen Persisting Perception Disorder: Etiology, Clinical ...
Mar 16, 2018 · The prevalence of this disorder is low; the condition is more often diagnosed in individuals with a history of previous psychological issues or ...
[111]
Prolonged adverse effects from repeated psilocybin use in an ...
Feb 28, 2025 · High doses of psychedelics have been identified as a risk factor for adverse events in naturalistic studies on PAEs [13]. Additionally, high ...Abstract · Discussion And Conclusions · Author InformationMissing: unpredictable | Show results with:unpredictable
[112]
Association of Hallucinogen Persisting Perception Disorder with ...
Nov 27, 2023 · Hallucinogen Persisting Perception Disorder (HPPD) is considered rare in hallucinogen users although there are conflicting reports about its ...
[113]
Association of Hallucinogen Persisting Perception Disorder with ...
We received 802 responses with 415 of these containing adequate data for further analysis. 39.7% of responders reported symptoms corresponding to Type I HPPD, ...
[114]
The Controlled Substances Act (CSA): A Legal Overview for the ...
Jan 22, 2025 · The Controlled Substances Act (CSA) establishes a unified legal framework to regulate certain drugs and other substances that are deemed to pose a risk of ...
[115]
Psychedelics, the Law and Politics - UC Berkeley BCSP
But just as the Controlled Substances Act ended most research into psychedelics in the United States, the 1971 Convention almost entirely halted efforts to ...
[116]
Psychedelics Drug Legislative Reform ant legalization in the US - PMC
The Controlled Substances Act of 1970 (CSA), established federal control over possession, distribution, and production of drugs. Shortly thereafter, the ...
[117]
Psychedelics: Where we are now, why we got here, what we must do
Feb 21, 2018 · These regulatory controls severely constrained development of psychedelic substances and their potential for clinical research in psychiatric ...Missing: impact | Show results with:impact
[118]
Drug War History - Drug Policy Alliance
Nixon Declared a War on Drugs. In June 1971, President Nixon declared a “war on drugs.” He increased the size, presence, and funding of federal drug control ...Missing: moral panic<|control11|><|separator|>
[119]
Oregon Health Authority : Oregon Psilocybin Services
The Oregon Psilocybin Services Section implements Ballot Measure 109 (now codified as ORS 475A), which was passed in November 2020 and directs the Oregon ...Access Psilocybin · Licensee Directory · Facilitator LicenseMissing: decriminalization | Show results with:decriminalization
[120]
Oregon Measure 109, Psilocybin Mushroom Services Program ...
As of 2020, the manufacturing and consumption of psilocybin was illegal under both federal law and state law. Under Measure 109, the Oregon Health Authority ( ...
[121]
Psychedelics Legalization & Decriminalization Tracker
Resolutions unanimously passed in the cities of Oakland, Santa Cruz, Arcata, Berkeley, and San Francisco have made personal use and possession of certain ...
[122]
Washington cities are decriminalizing magic mushrooms. Could a ...
May 13, 2025 · Statewide efforts to legalize psychedelic mushrooms in Washington have stalled due to conflicting visions, concerns about cost and equity.
[123]
Promise and caution in the new psychedelic renaissance
Clinical settings consistently report better outcomes than unsupervised use. In a sample of 698 individuals, co-use of MDMA with psilocybin or LSD was ...Missing: debates | Show results with:debates
[124]
Harm reduction practises for users of psychedelic drugs: a scoping ...
Oct 3, 2025 · People reported different forms of emotional support ranging from formal guides (most likely in ceremonial settings), trip sitters (either ...
[125]
The safety of supported psilocybin use in Oregon - PMC
They point to the fact that Ballot Measure 109 precluded requiring diagnosis to access psilocybin services and that Oregon regulations prohibit facilitators ...Missing: set | Show results with:set
[126]
An international Delphi consensus for reporting of setting ... - PubMed
Jun 3, 2025 · This study aimed to generate consensus-based guidelines for reporting settings in psychedelic clinical research, according to an international ...
[127]
Psychedelic minimalism: the case against music in ... - Frontiers
I argue that music introduces external emotional content that may obscure the patient's natural psychological flow, their set, thereby undermining the core ...Missing: experiments | Show results with:experiments
[128]
New guidelines for psychedelics trials aim to be 'gold standard' - News
Jun 3, 2025 · The overall aim is for the guidelines to become the standard in the field and encourage the reporting of contextual factors in future studies.
[129]
New Guidelines to Make Psychedelic Trials Safer, FDA-Ready
Jun 17, 2025 · An international expert panel has developed the first consensus-based framework for reporting “set and setting” variables in psychedelic clinical trials.
[130]
New Guidelines Aim to Standardize Psychedelic Clinical Trials
Jun 30, 2025 · The aim is to improve consistency in trial design and reporting, enhancing the ability to interpret and replicate findings. A lack of ...
[131]
Predicting Reactions to Psychedelic Drugs: A Systematic Review of ...
The current systematic review coalesced the results of 14 studies that included baseline states or traits predictive of the acute effects of psychedelics.
[132]
Set and setting of psychedelics for therapeutic use in psychiatry
May 12, 2025 · We describe the set and setting for therapeutic use of psychedelic drugs in people with psychiatric disorders.Missing: differential | Show results with:differential
[133]
Set and setting of psychedelics for therapeutic use in psychiatry
Sep 3, 2025 · We describe the set and setting for therapeutic use of psychedelic drugs in people with psychiatric disorders. In this systematic review, ...<|control11|><|separator|>
[134]
Knowledge gaps in psychedelic medicalisation: Clinical studies and ...
Set and setting. In most, if not all, clinical trials with psychedelics an interdisciplinary treatment model has been used, where psychedelic drugs are ...
[135]
Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI
Aug 18, 2023 · Beyond analysis and prediction, AI can uncover new molecular targets for psychedelics, model psychedelic–brain network interactions, or simulate ...
[136]
The Psychedelic Renaissance and Its Forensic Implications
Sep 1, 2025 · A practical and relevant concept to consider, first defined by Timothy Leary in the 1960s, is “set and setting.” Set refers to an individual's ...Missing: origin | Show results with:origin
[137]
Psychiatric risks for worsened mental health after psychedelic use
Resurgent psychedelic research has largely supported the safety and efficacy of psychedelic therapy for the treatment of various psychiatric disorders.
[138]
Naturalistic use of psychedelics in the general population
Jan 23, 2025 · Lorna Staines discusses a longitudinal population-based study examining the risks of using psychedelics in a naturalistic setting.
[139]
Talking to Your Patients About Psychedelics: Using an Informed ...
Oct 15, 2024 · Phase 2 clinical trials have reported efficacy for psilocybin-assisted therapy for treatment-resistant depression (TRD),18 MDD,19 and alcohol ...